scholarly journals Correlation between Eicosanoids in Bronchoalveolar Lavage Fluid and in Exhaled Breath Condensate

2011 ◽  
Vol 30 (5) ◽  
pp. 213-220 ◽  
Author(s):  
Adam Antczak ◽  
Wojciech Piotrowski ◽  
Jerzy Marczak ◽  
Maciej Ciebiada ◽  
Pawel Gorski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Chronic Cough ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Exhaled Breath Condensate ◽  
Lavage Fluid ◽  
Exhaled Breath ◽  
Strong Positive Correlation ◽  
Breath Condensate

Exhaled breath condensate (EBC) has been increasingly used as a new and non-invasive method to study airway inflammation. In this study we have compared the concentrations of lipid mediators in EBCwith concentrations in bronchoalveolar lavage fluid (BALF).We included 37 patients undergoing bronchoscopy (12 sarcoidosis, 12 COPD, 6 lung cancer, 5 chronic cough, 1 Wegener’s granulomatosis, 1 sclerodermia). Patients were not allowed to have exacerbation or any change in concomitant medication for at least 4 weeks prior to the study. In all patients, EBC was collected immediately prior to the bronchoscopy.The levels of cys-LTs, LTB4, 8-isoprostane were significantly higher in BALF compared to EBC (p < 0.0001, p < 0.001, p < 0.0001 for cys-LTs, LTB4, 8-isoprostane respectively). Moreover, there was a strong positive correlation between both leukotriene B4and 8-isoprostane in BALF and EBC (r= 0.53 andr= 0.79, p < 0.01, respectively) in patients with sarcoidosis and COPD but there was no correlation between eicosanoids BALF and EBC in patients with chronic cough and lung cancer.This is the first study to compare EBC and BALF in different lung diseases which demonstrated significant correlations between the levels of eicosanoids in BALF and EBCin patientswith COPD and sarcoidosis. EBC may be useful inmeasuring inflammation in several inflammatory lung diseases.

scholarly journals Eicosanoids in Exhaled Breath Condensate and Bronchoalveolar Lavage Fluid of Patients with Primary Lung Cancer

2012 ◽  
Vol 32 (5) ◽  
pp. 329-335 ◽  
Author(s):  
Maciej Ciebiada ◽  
Paweł Górski ◽  
Adam Antczak
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Bronchoalveolar Lavage Fluid ◽  
Exhaled Breath Condensate ◽  
Primary Lung Cancer ◽  
Lavage Fluid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Exhaled Breath ◽  
Lung Carcinogenesis ◽  
Breath Condensate

Although eicosanoids are involved in lung carcinogenesis they were poorly investigated in exhaled breath condensate (EBC) and bronchoalveolar lavage fluid (BALf) in patients with primary lung cancer. In this study 17 patients with diagnosed non-small cell lung cancer, 10 healthy smokers and 12 healthy nonsmokers were included. The levels of cys-LTs, 8-isoprostane, LTB4 and PGE2 were measured before any treatment in the EBC of all patients and in BALf of patients with lung cancer by enzyme linked immunosorbent assay. 8-isoprostane, LTB4, cys-LTs and PGE2 were detectable in the EBC and BALf. There were no significant differences between healthy smokers and nonsmokers in concentrations of all measured mediators. Compared with both healthy controls, patients with diagnosed lung cancer displayed higher concentrations of cys-LTs (p< 0.05) and LTB4 (p< 0.05) in EBC. In patients with lung cancer, the mean concentrations of all measured mediators were significantly higher in BALf compared with EBC and there was a significant, positive correlation between concentration of cys-LTs, LTB4and 8-isoprostane in BALf and their concentrations in the EBC (r= 0.64,p< 0.05,r= 0.59,p< 0.05,r= 0.53,p< 0.05 respectively). Since cys-LT, LTB4 and 8-isoprostane concentrations in EBC from patients with lung cancer reflect their concentrations in BALf, they may serve as a possible non-invasive method to monitor the disease and to assess the effectiveness of therapy.

scholarly journals Caution in Using Proteins Extracted from Exhaled Breath Condensate of Intubated Patients for Pediatric ARDS Studies

2020 ◽  
Author(s):  
Mohit Ojha ◽  
Rashika Joshi ◽  
Brian Michael Varisco
Keyword(s):  
Bronchoalveolar Lavage ◽  
Bronchoalveolar Lavage Fluid ◽  
Exhaled Breath Condensate ◽  
Invasive Mechanical Ventilation ◽  
Lavage Fluid ◽  
Exhaled Breath ◽  
Silver Stain ◽  
Discrete Band ◽  
Breath Condensate

Abstract Objective We sought to analyze the quality of proteins extracted from the humidified moisture exchange filter (HMEF) of pediatric acute respiratory distress syndrome (PARDS) patients undergoing invasive mechanical ventilation.Results Proteins were extracted from ten filters from one control and six PARDS subjects. Between 0.69-1.69 mg of protein was extracted from each. Silver stain of these extracts identified only one discrete band compared to many discrete bands in mouse BALF. Liquid chromatography- mass spectrometry of this band and a corresponding band in mouse bronchoalveolar lavage fluid identified them as human and mouse albumin respectively. Multiple other non-degraded proteins were obvious in mouse bronchoalveolar lavage fluid but not proteins extracted from HMEFs.

scholarly journals Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11528
Author(s):  
Wen-Jun Zhu ◽  
Bo-Jiang Chen ◽  
Ying-Ying Zhu ◽  
Ling Sun ◽  
Yu-Chen Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Roc Curve ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Background MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis. Methods BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ±  0.55 versus 0.07 ±  0.48, respectively, p < 0.001) as well as in lung cancer patients with stage I–IIA disease than in those with stage IIB–IV disease (0.98 ±  0.64 versus 0.66 ±  0.54, respectively, p < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I–IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.

Sign in / Sign up

Export Citation Format

Share Document